Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
New Approaches Towards Immunotherapy Give Hope in Fight Against Solid Tumors

VANCOUVER – USA News Group – Hope is on the horizon for revolutionary treatments meant to target solid tumors, which have historically been some the toughest cancers to treat. Beyond extending life...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.45 (+3.57%)
GILD : 64.80 (+0.51%)
BNTX : 166.96 (+5.57%)
NVS : 91.46 (+0.22%)
BMY : 76.14 (-1.87%)
HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients

Palm Beach, FL – May 4, 2022 – FinancialNewsMedia.com News Commentary – Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.45 (+3.57%)
BLTE : 14.53 (-1.09%)
ENDP : 0.4700 (-0.19%)
CLVS : 0.6900 (+2.34%)
PFE : 53.91 (-0.15%)
Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep’s Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study    Statistically significant increases...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.45 (+3.57%)
New Developments in Solid Tumor Therapeutics Continue to Give Hope to Patients

USA News Group – Hope is on the horizon for revolutionary treatments meant to target solid tumors, which have historically been some the toughest cancers to treat. Beyond extending life expectancy, the...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.45 (+3.57%)
GILD : 64.80 (+0.51%)
BNTX : 166.96 (+5.57%)
NVS : 91.46 (+0.22%)
BMY : 76.14 (-1.87%)
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing

Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.45 (+3.57%)
GSK : 44.06 (-0.81%)
SRRA : 54.78 (+0.09%)
ATRS : 5.59 (unch)
CLVS : 0.6900 (+2.34%)
TPTX : 36.16 (+10.92%)
Oncolytics Biotech® Announces Publication of Preclinical Data Demonstrating the Synergistic Anti-Cancer Activity of Pelareorep Combined with CAR T Cell Therapy in Solid Tumors in Science Translational Medicine

Pelareorep-CAR T combination may expand the commercial potential of CAR T cells to solid tumors   Combining CAR T cells with pelareorep prevented antigen escape by creating CAR T cells with dual specificity...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.45 (+3.57%)
Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer

Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.45 (+3.57%)
SPPI : 0.7375 (+4.57%)
LBPS : 3.31 (-1.78%)
REVB : 0.5321 (-1.10%)
CELZ : 0.9294 (-4.19%)
Oncolytics Biotech® Partner Adlai Nortye Advances Chinese Bridging Trial of Pelareorep-Paclitaxel Combination Treatment in Breast Cancer to Final Dosing Cohort

First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date   Trial is designed to satisfy regulatory requirements and accelerate...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.45 (+3.57%)
Biotech Innovators Making Strides Towards Meeting Increased Demand for Breast Cancer Treatments

VANCOUVER – USA News Group – Last year in 2021, an estimated 281,550 new cases of invasive breast cancer were expected to be diagnosed in American women, according to the American Cancer Society. A...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.45 (+3.57%)
PFE : 53.91 (-0.15%)
AZN : 67.40 (+1.05%)
GILD : 64.80 (+0.51%)
PBYI : 2.0700 (+5.61%)
Promising Developments in Treating Multiple Myeloma Coming at This Year’s AACR Meeting

VANCOUVER – USA News Group –According to a report from ResearchAndMarkets.com, total cases of the uncommon but deadly blood cancer, multiple myeloma, will continue to rise by 2030. Treatment for the...

ONCY : 1.1200 (+3.70%)
ONC.TO : 1.45 (+3.57%)
CGEN : 1.8700 (+10.00%)
CCCC : 7.39 (+5.42%)
AMGN : 255.26 (+0.87%)
JNJ : 181.09 (+0.91%)

Barchart Exclusives

This Week’s Unusual Options Activity Leaves Investors Thirsting for More
If you’re looking for a reasonably quick return from your call option bet, the unusual options activity on May 27 suggests Wendy’s is your best bet.  Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar